Siltuximab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Siltuximab |
| DrugBank ID | DB09036 |
| Brand Names (EU) | Sylvant |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.82% |
Approved Indication (EMA)
Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Kimura disease | 99.82% | DL |
| 2 | extracutaneous mastocytoma | 99.64% | DL |
| 3 | hepatic infarction | 99.44% | DL |
| 4 | hepatic veno-occlusive disease | 99.40% | DL |
| 5 | Castleman disease | 99.39% | DL |
| 6 | peliosis hepatis | 99.29% | DL |
| 7 | Kaposi’s sarcoma (disease) | 99.28% | DL |
| 8 | autosomal recessive familial Mediterranean fever | 99.22% | DL |
| 9 | aggressive systemic mastocytosis | 99.16% | DL |
| 10 | autosomal dominant familial periodic fever | 99.05% | DL |
| 11 | syndrome with combined immunodeficiency | 98.85% | DL |
| 12 | TAFRO syndrome | 98.79% | DL |
| 13 | dermatofibrosarcoma protuberans | 98.76% | DL |
| 14 | lymphangiomyoma | 98.67% | DL |
| 15 | benign PEComa | 98.66% | DL |
| 16 | uterine corpus perivascular epithelioid cell tumor | 98.64% | DL |
| 17 | primary release disorder of platelets | 98.56% | DL |
| 18 | hepatic veno-occlusive disease-immunodeficiency syndrome | 98.48% | DL |
| 19 | pancytopenia due to IKZF1 mutations | 98.40% | DL |
| 20 | periodic fever-infantile enterocolitis-autoinflammatory syndrome | 98.40% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.